Susceptibility of HIV-1 subtypes B′, CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Yu, Xiaoling ^a,b   Yuan, Lin ^a   Huang, Yang ^a   Xu, Weisi ^a   Fang, Zhiming ^a   Liu, Shuwen ^b   Shao, Yiming ^a   Jiang, Shibo ^b,c,d   Ma, Liying ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c NEW YORK BLOOD CENTER   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C 34; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; RECOMBINANT DNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINA; CONTROLLED STUDY; ENVELOPE GENE; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 B; HUMAN IMMUNODEFICIENCY VIRUS 1 CRF01 AE; HUMAN IMMUNODEFICIENCY VIRUS 1 CRF07 BC; IC 50; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PHYLOGENETIC TREE; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN; AMINO ACID SEQUENCE; CHEMISTRY; CLASSIFICATION; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; MOLECULAR GENETICS; PHENOTYPE; PHYLOGENY; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AMINO ACID SEQUENCE; CHINA; DNA, RECOMBINANT; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHENOTYPE; PHYLOGENY; POLYMORPHISM, GENETIC; SEQUENCE ALIGNMENT;

EID: 79952584263     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017605     Document Type: Article

References (50)

1. McCutchan FE, (2000) Understanding the genetic diversity of HIV-1. AIDS 14 (Suppl 3): S31-44.
2. Taylor BS, Hammer SM, (2008) The challenge of HIV-1 subtype diversity. N Engl J Med 359: 1965-1966.
3. Liao L, Xing H, Shang H, Li J, Zhong P, et al. (2010) The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 53 (Suppl 1): S10-14.
4. Lu L, Jia M, Ma Y, Yang L, Chen Z, et al. (2008) The changing face of HIV in China. Nature 455: 609-611.
5. Schurmann D, Fatkenheuer G, Reynes J, Michelet C, Raffi F, et al. (2007) Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 21: 1293-1299.
6. Pang W, Tam SC, Zheng YT, (2009) Current peptide HIV type-1 fusion inhibitors. Antivir Chem Chemother 20: 1-18.
7. Pan C, Cai L, Lu H, Qi Z, Jiang S, (2009) Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and-resistant HIV type 1 strains. J Virol 83: 7862-7872.
8. Harrison SC, (2008) Viral membrane fusion. Nat Struct Mol Biol 15: 690-698.
9. Jiang S, Lin K, Strick N, Neurath AR, (1993) HIV-1 inhibition by a peptide. Nature 365: 113.
10. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ, (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91: 9770-9774.
11. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, et al. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348: 2175-2185.
12. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, et al. (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348: 2186-2195.
13. Li T, Dai Y, Kuang J, Jiang J, Han Y, et al. (2008) Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. PLoS One 3: e3918.
14. Zhang F, Dou Z, Yu L, Xu J, Jiao JH, et al. (2008) The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 47: 825-833.
15. Luo M, Liu H, Zhuang K, Liu L, Su B, et al. (2009) Prevalence of drug-resistant HIV-1 in rural areas of Hubei province in the People's Republic of China. J Acquir Immune Defic Syndr 50: 1-8.
16. Han J, Wang L, Jiang Y, Zhang Q, Fang L, et al. (2009) Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China. Int J STD AIDS 20: 249-254.
17. Zhang M, Han XX, Cui WG, Jia MH, Meng XD, et al. (2008) The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation. Jpn J Infect Dis 61: 361-365.
18. Rimsky LT, Shugars DC, Matthews TJ, (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72: 986-993.
19. Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R, (2007) Evolution of China's response to HIV/AIDS. Lancet 369: 679-690.
20. Shao Y, (2006) AIDS epidemic at age 25 and control efforts in China. Retrovirology 3: 87.
21. Ma L, Huang J, Xing H, Yuan L, Yu X, et al. (2010) Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B′ strains from former blood donors in central Chinese provinces. AIDS Res Hum Retroviruses 26: 1007-1013.
22. Sun J, Ma L, Yu X, Huang Y, Yuan L, et al. (2009) Replication and drug resistant mutation of HIV-1 subtype B′ (Thailand B) variants isolated from HAART treatment individuals in China. Virol J 6: 201.
23. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11: 1170-1172.
24. Kromdijk W, Huitema AD, Mulder JW, (2010) Treatment of HIV infection with the CCR5 antagonist maraviroc. Expert Opin Pharmacother 11: 1215-1223.
25. Liu S, Lu H, Niu J, Xu Y, Wu S, et al. (2005) Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 280: 11259-11273.
26. Liu S, Jing W, Cheung B, Lu H, Sun J, et al. (2007) HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem 282: 9612-9620.
27. He Y, Xiao Y, Song H, Liang Q, Ju D, et al. (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283: 11126-11134.
28. Cai L, Jiang S, (2010) Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem 5: 1813-1824.
29. Eggink D, Langedijk JP, Bonvin AM, Deng Y, Lu M, et al. (2009) Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem 284: 26941-26950.
30. Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, et al. (2009) Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. J Biol Chem 284: 4914-4920.
31. Shimura K, Nameki D, Kajiwara K, Watanabe K, Sakagami Y, et al. (2010) Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J Biol Chem.
32. Liu Z, Shan M, Li L, Lu L, Meng S, et al. (2010) In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem.
33. Ray N, Blackburn LA, Doms RW, (2009) HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J Virol 83: 2989-2995.
34. Leung PH, Chen JH, Wong KH, Chan KC, Lam HY, et al. (2010) High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong. J Clin Virol 47: 273-275.
35. Carmona R, Perez-Alvarez L, Munoz M, Casado G, Delgado E, et al. (2005) Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 32: 248-253.
36. Toma J, Whitcomb JM, Petropoulos CJ, Huang W, (2010) Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors. AIDS 24: 2181-2186.
37. Levin J, Symons J, van Lelyveld S, Hoepelman AIM, van Ham P, et al. (2010) Maraviroc fully inhibits dual-R5 virus in dual/mixed HIV-1 infected patient. 17th CROI Conference on Retroviruses and Opportunistic Infections, San Francisco CA, February 16-19, 2010http://www.natap.org/2010/CROI/croi_113.htm.
38. Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ, (2007) Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol 81: 8258-8269.
39. Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, et al. (2008) In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 82: 8210-8214.
40. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, et al. (2004) Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 78: 2790-2807.
41. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, et al. (2006) Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80: 4909-4920.
42. Ogert RA, Wojcik L, Buontempo C, Ba L, Buontempo P, et al. (2008) Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373: 387-399.
43. Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP, (2009) Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A 106: 5318-5323.
44. Princen K, Hatse S, Vermeire K, De Clercq E, Schols D, (2004) Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology 1: 2.
45. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, et al. (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37: 1253-1262.
46. Ma L, Guo Y, Yuan L, Huang Y, Sun J, et al. (2009) Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China. Retrovirology 6: 45.
47. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, et al. (2002) Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16: 1511-1519.
48. Chong H, Hong K, Zhang C, Nie J, Song A, et al. (2008) Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J Acquir Immune Defic Syndr 47: 535-543.
49. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
50. Ma L, Sun J, Xing H, Si X, Yuan L, et al. (2007) Genotype and phenotype patterns of drug-resistant HIV-1 subtype B′ (Thai B) isolated from patients failing antiretroviral therapy in China. J Acquir Immune Defic Syndr 44: 14-19.